Alpha IVF Group Berhad

KLSE:ALPHA Stock Report

Market Cap: RM 1.5b

Alpha IVF Group Berhad Valuation

Is ALPHA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALPHA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

RM 0.14
Fair Value
116.9% overvalued intrinsic discount
3
Number of Analysts

Below Fair Value: ALPHA (MYR0.3) is trading above our estimate of fair value (MYR0.14)

Significantly Below Fair Value: ALPHA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALPHA?

Key metric: As ALPHA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALPHA. This is calculated by dividing ALPHA's market cap by their current earnings.
What is ALPHA's PE Ratio?
PE Ratio25x
EarningsRM 58.35m
Market CapRM 1.46b

Price to Earnings Ratio vs Peers

How does ALPHA's PE Ratio compare to its peers?

The above table shows the PE ratio for ALPHA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.2x
TMCLIFE TMC Life Sciences Berhad
147.4xn/aRM 749.0m
OPTIMAX Optimax Holdings Berhad
24.1x18.71%RM 323.3m
METRO Metro Healthcare Berhad
75.8x24.02%RM 230.0m
HONGSENG Hong Seng Consolidated Berhad
1.4xn/aRM 51.1m
ALPHA Alpha IVF Group Berhad
25x23.51%RM 1.5b

Price-To-Earnings vs Peers: ALPHA is good value based on its Price-To-Earnings Ratio (25x) compared to the peer average (62.2x).

Price to Earnings Ratio vs Industry

How does ALPHA's PE Ratio compare vs other companies in the Asian Healthcare Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ALPHA 25.0xIndustry Avg. 19.2xNo. of Companies68PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ALPHA is expensive based on its Price-To-Earnings Ratio (25x) compared to the Asian Healthcare industry average (19.2x).

Price to Earnings Ratio vs Fair Ratio

What is ALPHA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALPHA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25x
Fair PE Ratio28.6x

Price-To-Earnings vs Fair Ratio: ALPHA is good value based on its Price-To-Earnings Ratio (25x) compared to the estimated Fair Price-To-Earnings Ratio (28.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALPHA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentRM 0.30
RM 0.42
+40.00%
1.94%RM 0.43RM 0.41n/a3
Nov ’26RM 0.33
RM 0.42
+27.27%
1.94%RM 0.43RM 0.41n/a3
Oct ’26RM 0.33
RM 0.37
+13.13%
7.03%RM 0.41RM 0.35n/a3
Sep ’26RM 0.30
RM 0.37
+24.44%
7.03%RM 0.41RM 0.35n/a3
Aug ’26RM 0.29
RM 0.38
+31.03%
7.89%RM 0.41RM 0.35n/a2
Jul ’26RM 0.28
RM 0.38
+38.18%
7.89%RM 0.41RM 0.35n/a2
Jun ’26RM 0.28
RM 0.38
+35.71%
7.89%RM 0.41RM 0.35n/a2
May ’26RM 0.28
RM 0.39
+38.01%
7.86%RM 0.42RM 0.35n/a3
Apr ’26RM 0.33
RM 0.41
+26.15%
1.99%RM 0.42RM 0.40n/a3
Mar ’26RM 0.30
RM 0.41
+36.67%
1.99%RM 0.42RM 0.40n/a3
Feb ’26RM 0.32
RM 0.41
+30.16%
1.99%RM 0.42RM 0.40n/a3
Jan ’26RM 0.34
RM 0.41
+20.59%
2.44%RM 0.42RM 0.40n/a2
Dec ’25RM 0.34
RM 0.41
+22.39%
2.44%RM 0.42RM 0.40n/a2
Nov ’25RM 0.35
RM 0.41
+17.14%
2.44%RM 0.42RM 0.40RM 0.332
Oct ’25RM 0.36
RM 0.40
+9.59%
4.08%RM 0.42RM 0.38RM 0.333
Sep ’25RM 0.32
RM 0.40
+25.00%
4.08%RM 0.42RM 0.38RM 0.303
Aug ’25RM 0.33
RM 0.40
+23.08%
4.08%RM 0.42RM 0.38RM 0.293
Jul ’25RM 0.31
RM 0.40
+29.03%
4.08%RM 0.42RM 0.38RM 0.283
Jun ’25RM 0.32
RM 0.40
+26.98%
4.08%RM 0.42RM 0.38RM 0.283
May ’25RM 0.33
RM 0.40
+23.08%
4.08%RM 0.42RM 0.38RM 0.283
RM 0.42
Fair Value
28.6% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/30 17:16
End of Day Share Price 2025/11/28 00:00
Earnings2025/08/31
Annual Earnings2025/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alpha IVF Group Berhad is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li-Ching FoongPublic Investment Bank Berhad
Siao LeePublic Investment Bank Berhad
Kong TanTA Securities Holdings Berhad